Evolus, Inc.(EOLS)

Drug Manufacturers - Specialty & Generic · Newport Beach, CA

$7.39-0.08 (-1.07%)

Delayed quote: Oct 6, 2026, 3:55 PM EDT

Evolus (EOLS) Price/FCF Ratio: History & Chart | TGMCharts

Price/FCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/FCF ratio is N/A as of 2026-10-06T19:56:37.281Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:56:37.281Z.

Quote observation: 2026-10-06T19:55:23.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 486,666,610
TTM free cash flow · period ending 2026-06-30: -22,622,000

FMP input reference: c1a6838803f42d6ea125a2cca62df7e150df7eb7d5f2d1fff74d5c1a91b3d340

P/E Ratio|FCF Growth|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

EOLS Price/FCF Ratio Metrics

PRICE/FCF RATIO

N/A

EOLS Competitors' Price/FCF Ratio

EOLS

Evolus, Inc.

Current

Market Cap

$486.67M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PBYI

Puma Biotechnology, Inc.

vs EOLS

Market Cap

$483.80M

Price/FCF Ratio

11.78

TTM Avg

8.08

3Y Avg

11.34

5Y Avg

14.47

OCS

Oculis Holding AG

vs EOLS

Market Cap

$494.52M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTNM

Contineum Therapeutics, Inc.

vs EOLS

Market Cap

$475.15M

Price/FCF Ratio

N/A

TTM Avg

26.42

3Y Avg

26.42

5Y Avg

26.42

TCMD

Tactile Systems Technology, Inc.

vs EOLS

Market Cap

$499.40M

Price/FCF Ratio

18.69

TTM Avg

15.64

3Y Avg

12.14

5Y Avg

236.08

DRUG

Bright Minds Biosciences Inc.

vs EOLS

Market Cap

$472.82M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALLO

Allogene Therapeutics, Inc.

vs EOLS

Market Cap

$503.93M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ARVN

Arvinas, Inc.

vs EOLS

Market Cap

$471.65M

Price/FCF Ratio

N/A

TTM Avg

5.51

3Y Avg

5.54

5Y Avg

11.44

CBIO

Crescent Biopharma, Inc.

vs EOLS

Market Cap

$504.04M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TKNO

Alpha Teknova, Inc.

vs EOLS

Market Cap

$469.68M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
Evolus, Inc. (EOLS)	$486.67M	N/A	N/A	N/A	N/A
Puma Biotechnology, Inc. (PBYI)vs ›	$483.80M	11.78	8.08	11.34	14.47
Oculis Holding AG (OCS)vs ›	$494.52M	N/A	N/A	N/A	N/A
Contineum Therapeutics, Inc. (CTNM)vs ›	$475.15M	N/A	26.42	26.42	26.42
Tactile Systems Technology, Inc. (TCMD)vs ›	$499.40M	18.69	15.64	12.14	236.08
Bright Minds Biosciences Inc. (DRUG)vs ›	$472.82M	N/A	N/A	N/A	N/A
Allogene Therapeutics, Inc. (ALLO)vs ›	$503.93M	N/A	N/A	N/A	N/A
Arvinas, Inc. (ARVN)vs ›	$471.65M	N/A	5.51	5.54	11.44
Crescent Biopharma, Inc. (CBIO)vs ›	$504.04M	N/A	N/A	N/A	N/A
Alpha Teknova, Inc. (TKNO)vs ›	$469.68M	N/A	N/A	N/A	N/A

Free Cash Flow Valuation

P/FCF Ratio

N/A

FCF Yield

N/A

Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Price/FCF Ratio: N/A

EOLS Price/FCF Ratio Metrics

EOLS Competitors' Price/FCF Ratio

Free Cash Flow Valuation

Price/FCF Ratio Formula & Definition

Related Metrics